Mirati’s adagrasib spurs 41% response in pancreatic, GI tumors, scoring points where KRAS leader Amgen hasn’t gone

Mirati's adagrasib spurs 41% response in pancreatic, GI tumors, scoring points where KRAS leader Amgen hasn't gone klahucik Fri, 01/21/2022 - 11:08

Click to view original post